Shares of CVS Health Corporation (NYSE:CVS) have earned a consensus recommendation of “Buy” from the twenty-two brokerages that are covering the firm, MarketBeat.com reports. Nine research analysts have rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $91.23.

Several equities analysts recently issued reports on the stock. Vetr downgraded shares of CVS Health Corporation from a “buy” rating to a “hold” rating and set a $85.78 price target for the company. in a report on Thursday, April 27th. Tigress Financial assumed coverage on shares of CVS Health Corporation in a report on Thursday, April 27th. They set a “buy” rating for the company. Needham & Company LLC assumed coverage on shares of CVS Health Corporation in a report on Tuesday, June 27th. They set a “hold” rating for the company. Guggenheim reissued a “buy” rating on shares of CVS Health Corporation in a report on Monday, July 3rd. Finally, Leerink Swann set a $90.00 price target on shares of CVS Health Corporation and gave the company a “buy” rating in a report on Tuesday, June 27th.

ILLEGAL ACTIVITY WARNING: “CVS Health Corporation (CVS) Receives $91.23 Consensus PT from Brokerages” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/08/07/cvs-health-corporation-cvs-receives-91-23-consensus-pt-from-brokerages.html.

In related news, CFO David M. Denton sold 230,510 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $80.00, for a total transaction of $18,440,800.00. Following the completion of the transaction, the chief financial officer now owns 176,983 shares in the company, valued at $14,158,640. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Helena Foulkes sold 20,333 shares of the business’s stock in a transaction that occurred on Monday, June 26th. The shares were sold at an average price of $80.00, for a total transaction of $1,626,640.00. Following the transaction, the executive vice president now owns 59,301 shares of the company’s stock, valued at approximately $4,744,080. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 271,175 shares of company stock valued at $21,632,597. Corporate insiders own 0.61% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of CVS. Norges Bank purchased a new position in shares of CVS Health Corporation during the fourth quarter worth about $800,355,000. Boston Partners boosted its position in shares of CVS Health Corporation by 69.1% in the second quarter. Boston Partners now owns 6,459,237 shares of the pharmacy operator’s stock worth $519,711,000 after buying an additional 2,638,888 shares in the last quarter. LSV Asset Management boosted its position in shares of CVS Health Corporation by 44.2% in the first quarter. LSV Asset Management now owns 4,579,916 shares of the pharmacy operator’s stock worth $359,523,000 after buying an additional 1,404,384 shares in the last quarter. Macquarie Group Ltd. boosted its position in shares of CVS Health Corporation by 16.6% in the fourth quarter. Macquarie Group Ltd. now owns 9,526,280 shares of the pharmacy operator’s stock worth $751,719,000 after buying an additional 1,359,100 shares in the last quarter. Finally, Canada Pension Plan Investment Board boosted its position in shares of CVS Health Corporation by 89.8% in the second quarter. Canada Pension Plan Investment Board now owns 1,851,099 shares of the pharmacy operator’s stock worth $148,939,000 after buying an additional 876,027 shares in the last quarter. Hedge funds and other institutional investors own 81.92% of the company’s stock.

Shares of CVS Health Corporation (NYSE:CVS) traded up 0.94% during midday trading on Friday, hitting $78.70. 1,750,680 shares of the company’s stock traded hands. The company has a 50 day moving average price of $78.75 and a 200 day moving average price of $79.09. The firm has a market capitalization of $80.18 billion, a price-to-earnings ratio of 16.41 and a beta of 0.91. CVS Health Corporation has a 1-year low of $69.30 and a 1-year high of $98.44.

The firm also recently declared a quarterly dividend, which was paid on Thursday, August 3rd. Investors of record on Monday, July 24th were paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.57%. The ex-dividend date was Thursday, July 20th. CVS Health Corporation’s dividend payout ratio (DPR) is 41.67%.

About CVS Health Corporation

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Analyst Recommendations for CVS Health Corporation (NYSE:CVS)

Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.